Last reviewed · How we verify

Brimonidine Tartrate 0.025% — Competitive Intelligence Brief

Brimonidine Tartrate 0.025% (Brimonidine Tartrate 0.025%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Ophthalmology.

phase 3 Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine Tartrate 0.025% (Brimonidine Tartrate 0.025%) — Eye Therapies, LLC. Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brimonidine Tartrate 0.025% TARGET Brimonidine Tartrate 0.025% Eye Therapies, LLC phase 3 Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
transdermal clonidine transdermal clonidine Peking University People's Hospital marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Nebulized lidocaine and dexmedetomidine Nebulized lidocaine and dexmedetomidine Ain Shams University marketed Local anesthetic and sedative-analgesic combination Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Oxymetazoline gel Oxymetazoline gel RDD Pharma Ltd marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Mirtazapine/SNRIs Mirtazapine/SNRIs Shanghai Mental Health Center marketed Tetracyclic antidepressant Alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Mirtazapine Tablets Mirtazapine Tablets National Institute of Mental Health, Dhaka marketed Tetracyclic antidepressant Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
Sufentanil and dexmedetomidine Sufentanil and dexmedetomidine Obstetrics & Gynecology Hospital of Fudan University marketed Opioid agonist and alpha-2 adrenergic agonist combination Mu opioid receptor and alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

  1. USWM, LLC (dba US WorldMeds) · 2 drugs in this class
  2. China International Neuroscience Institution · 1 drug in this class
  3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  4. Eye Therapies, LLC · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Guangzhou Women and Children's Medical Center · 1 drug in this class
  7. Derm Research, PLLC · 1 drug in this class
  8. Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
  9. KK Women's and Children's Hospital · 1 drug in this class
  10. American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine Tartrate 0.025% — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-tartrate-0-025. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: